Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Results of Operations and Financial Condition

0

Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.

Description

99.01 Press Release Dated August 8, 2017


Neuralstem, Inc. Exhibit
EX-99.01 2 exh_9901.htm PRESS RELEASE EdgarFilingExhibit 99.01Neuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical and Business Update GERMANTOWN,…
To view the full exhibit click here

About Neuralstem, Inc. (NASDAQ:CUR)

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.